There are two distinct versions: CJC1295 with DAC Drug Affinity Complex extends the half-life to ~8 days, allowing weekly injections , but lacks pulsatility CJC1295 without DAC Shorter half-life (~30 minutes), ideal for physiological GH pulses , and preferred in performance enhancement settings For athletic performance and recovery, CJC1295 without DAC is most often chosen due to its compatibility with GHRP2 , MK677 , and BPC157
This is infinitely more appealing than navigating a cold, corporate-looking website on your own
Side Effects and Safety Across all published research, ipamorelin has demonstrated a favorable safety profile: No significant cortisol or prolactin elevation at therapeutic doses No meaningful appetite stimulation Mild and transient side effects including headache, flushing, and injection site irritation No serious adverse events reported in published clinical trials at standard doses The main limitation is the absence of long-term safety data from large-scale human studies
Patients with diabetes, obesity, and existing atherosclerotic cardiovascular disease stand to benefit the most.